SB 2308: Relating to the establishment of a consortium to conduct United States Food and Drug Administration's drug development clinical trials with ibogaine to secure the administration's approval of the medication's use for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy and to the administration of that treatment.

Plain-language summary

SB 2308 is a bill introduced in the Texas Senate on March 11, 2025. According to its official title, it concerns: Relating to the establishment of a consortium to conduct United States Food and Drug Administration's drug development clinical trials with ibogaine to secure the administration's approval of the medication's use for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy and to the administration of that treatment. Primary sponsor: Tan Parker (Republican), Cody Harris (Republican), Jeff Leach (Republican), Dade Phelan (Republican), Angelia Orr (Republican), VanDeaver. It lists 30 additional sponsors. Most recent recorded action (June 11, 2025): Effective immediately.

Generated automatically from the official title, sponsor list, and status record only. It does not characterize the bill’s purpose or effects. How summaries are written